The field of cancer treatment is evolving at an astonishing pace, with groundbreaking developments taking centre stage at this year’s ESMO conference.
Among the most exciting and promising trends in cancer therapy are the combinations of Antibody-Drug Conjugates (ADCs) and Immuno-Oncology (IO) agents.
These innovative combinations have the potential to revolutionise the way we treat various cancer types and bring renewed hope to patients.
In our latest article, we discuss some of the key highlights from the conference and the implications of the latest advancements.
To read our thoughts in full, click here.